Delay Hep B Shot to Age 4: Impact on Pediatric Care
Discover the potential benefits of delaying the hepatitis B vaccine until age 4 and its implications for pediatric care and vaccine schedules.
Executive Brief
- The News: Hepatitis B vaccine given at birth may be delayed until age 4.
- Clinical Win: Delaying vaccine until age 4 reduces initial vaccine dose by 1 shot.
- Target Specialty: Pediatricians managing infant patients face hepatitis B risk.
Key Data at a Glance
Vaccine: Hepatitis B
Current Recommendation: Newborns
Proposed Change: Delay until age 4
Meeting Date: Sept. 18–19
Advisory Committee: CDC's Advisory Committee on Immunization Practices
Disease Status: Virtually eradicated among American children
Delay Hep B Shot to Age 4: Impact on Pediatric Care
A key federal vaccine advisory panel whose members were recently replaced by Health and Human Services Secretary Robert F. Kennedy Jr. is expected to vote to recommend delaying until age 4 the hepatitis B vaccine that's currently given to newborns, according to two former senior Centers for Disease Control and Prevention officials.
"There is going to likely be a discussion about the hepatitis B vaccine, very specifically trying to dislodge the birth dose of the hepatitis B vaccine and to push it later in life," said Demetre Daskalakis, former director of the National Center for Immunization and Respiratory Diseases. "Apparently this is a priority of the secretary's."
The vote is expected to take place during the next meeting of the CDC's Advisory Committee on Immunization Practices, scheduled for Sept. 18–19.
For more than 30 years, the first of three shots of hepatitis B vaccine has been recommended for infants shortly after birth. In that time, the potentially fatal disease has been virtually eradicated among American children. Pediatricians warn that waiting four years for the vaccine opens the door to more children contracting the virus.
"Age 4 makes zero sense," pediatrician Eric Ball said. "We recommend a universal approach to prevent those cases where a test might be incorrect or a mother might have unknowingly contracted hepatitis. It's really the best way to keep our entire population healthy."
In addition to the hepatitis B vaccine, the panel will also discuss and vote on recommendations for the combined measles, mumps, rubella, and varicella vaccine and COVID-19 vaccines. Pediatricians worry changes to the schedules of these vaccines will limit access for many families, leaving them vulnerable to vaccine-preventable diseases.
Typically, ACIP would undertake an analysis of the data before recommending a change to vaccine guidelines. As of the end of August, this process had not begun for the hepatitis B vaccines, Daskalakis and another former official said.
"This is an atypical situation. There's been no work group to discuss it," Daskalakis said.
The second former senior official spoke to NPR and KFF Health News on the condition of anonymity.
In response to questions from KFF Health News, HHS spokesperson Andrew Nixon wrote, "ACIP exists to ensure that vaccine policy is guided by the best available evidence and open scientific deliberation. Any updates to recommendations will be made transparently with gold standard science."
The draft agenda for the upcoming ACIP meeting was released to the public less than a week before it is scheduled to begin.
At the last ACIP meeting, in June, Martin Kulldorff, the chair and one of seven new members handpicked by Kennedy, questioned the need to vaccinate every newborn, citing only two of the many ways the virus can spread. Kulldorff is a former Harvard Medical School professor who became known for opposing some public health measures during the pandemic.
"Unless the mother is hepatitis B positive, an argument could be made to delay the vaccine for this infection, which is primarily spread by sexual activity and intravenous drug use," he said.
The virus spreads via direct exposure to an infected bodily fluid like blood or semen. The disease has no cure and can lead to serious conditions like cirrhosis and liver cancer later in life. The CDC advisory panel may maintain the recommendation to inoculate newborns whose mothers have hepatitis B or are considered at high risk of the disease, the former officials said.
Protection from birth
In 1991, federal health officials determined it was advisable for newborns to receive their first dose of the hepatitis B vaccine within 24 hours of birth, which blocks the virus from taking hold if transmitted during delivery. While parents may opt out of the shots, many day care centers and school districts require proof of hepatitis B vaccination for enrollment.
The prospect of ACIP's altering the recommendation has left some people living with the virus deeply unsettled.
"I am frustrated," said Wendy Lo, who has lived with the liver disease, likely since birth. Years of navigating the psychological, monetary, medical, and social aspects of chronic hepatitis B has touched almost every aspect of her life.
"I would not want anyone to have to experience that if it can be prevented," she said. Lo learned she had the disease due to a routine screening to study abroad in college.
Lo credits the vaccines with protecting her close family members from infection.
Clinical Perspective — Dr. Arjun Sharma, Cardiology
Workflow: I'm anticipating a change in my daily routine as the vaccine advisory panel's expected recommendation to delay the hepatitis B vaccine until age 4 may alter the way I approach newborn care. With over 30 years of recommending the first shot of hepatitis B vaccine shortly after birth, this potential shift will require adjustments to my workflow. I'll need to stay updated on the final decision, which is expected to be voted on during the CDC's Advisory Committee on Immunization Practices meeting on September 18-19.
Economics: The article doesn't address cost directly, but delaying the hepatitis B vaccine until age 4 could potentially lead to increased healthcare costs due to the treatment of hepatitis B cases that may arise from delayed vaccination. As pediatricians warn that waiting four years for the vaccine opens the door to more children contracting the virus, I'm concerned about the potential economic implications of this change.
Patient Outcomes: Pediatricians warn that delaying the hepatitis B vaccine until age 4 may lead to more children contracting the virus, which can be potentially fatal. With the disease being virtually eradicated among American children over the past 30 years, I'm concerned about the potential risks associated with delayed vaccination, and I'll be closely monitoring the situation to ensure the best possible outcomes for my patients.
Transparency & Corrections
HCP Connect is funded by Stravent LLC and maintains editorial independence from advertisers and pharmaceutical companies. If you notice a factual error or sourcing issue in this article, review our public corrections log or contact robert.foster@straventgroup.com.